Jakub Flašík
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jakub Flašík has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Eva Kociánová
Department of Internal Medicine I – Cardiology, University Hospital Olomouc
1 shared publication - Jan Mizera
Department of Respiratory Medicine, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacký University Olomouc, Olomouc 779 00, Czech Republic
1 shared publication - Jan Olšr
Department of Internal Medicine I – Cardiology, University Hospital Olomouc
1 shared publication - Jan Václavík
Department of Internal Medicine and Cardiology, Ostrava University Hospital, Ostrava, Czech Republic (Jadrníčková, Václavík, and Dubský); Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic (Jadrníčková, Václavík, and Dubský)
1 shared publication - Libor Jelinek
Faculty of Medicine, Palacky University, Krizkovskeho 511/8, 779 00 Olomouc, Czech Republic
1 shared publication - Martin Modrák
Department of Bioinformatics, Second Faculty of Medicine, Charles University, Prague, Czech Republic
1 shared publication
Latest Publications
- Open Access
- 23 January 2026
- Published by Taylor & Francis in Blood Pressure
- Vol. 35 (1) , 1-16
Secondary causes and renal outcomes in apparently resistant hypertension: a retrospective cohort study
In this study, we aimed to determine the prevalence and spectrum of secondary hypertension among patients with apparently resistant arterial hypertension (aRH) and to compare the rate of decline in estimated glomerular filtration rate (eGFR) between those with primary aldosteronism (PA) and true resistant arterial hypertension (RAH). We conducted a retrospective cohort study of 790 patients with aRH referred to a hypertension excellence center. All patients fulfilled pharmacological criteria for aRH and underwent a screening protocol to evaluate secondary hypertension. We compared clinical and laboratory markers of patients with PA to those with RAH, with a median follow-up of 7 years. Secondary hypertension was identified in 213 patients (27%), with PA being the most common cause (17%), followed by renovascular hypertension (4.1%), renal parenchymal disease (3.7%), pheochromocytoma (0.8%), and Cushing's syndrome (0.6%). Compared to RAH patients, those with PA had significantly fewer cardiovascular comorbidities, lower serum potassium levels (4.13 vs. 4.23 mmol/L). Notably, patients with RAH exhibited a faster decline in renal function, specifically an additional 0.7 mL/min/1.73m2 reduction per year (95% CI 0.05 - 1.35, p = 0.03), despite similar baseline eGFR and BP control. In RAH, a continuous association between higher average 24-hour systolic BP and a faster decline in renal function was observed. Systematic screening in aRH reveals a high prevalence of secondary hypertension, particularly PA. Patients with RAH showed significantly worse renal outcomes compared to those with PA, with faster renal decline associated with higher blood pressure within the RAH group, underscoring the need for early diagnosis and strict BP management.
- 23 January 2026
- Published by Taylor & Francis in Blood Pressure
- Vol. 35 (1) , 1-16
Open AccessSecondary causes and renal outcomes in apparently resistant hypertension: a retrospective cohort study
In this study, we aimed to determine the prevalence and spectrum of secondary hypertension among patients with apparently resistant arterial hypertension (aRH) and to compare the rate of decline in estimated glomerular filtration rate (eGFR) between those with primary aldosteronism (PA) and true resistant arterial hypertension (RAH). We conducted a retrospective cohort study of 790 patients with aRH referred to a hypertension excellence center. All patients fulfilled pharmacological criteria for aRH and underwent a screening protocol to evaluate secondary hypertension. We compared clinical and laboratory markers of patients with PA to those with RAH, with a median follow-up of 7 years. Secondary hypertension was identified in 213 patients (27%), with PA being the most common cause (17%), followed by renovascular hypertension (4.1%), renal parenchymal disease (3.7%), pheochromocytoma (0.8%), and Cushing's syndrome (0.6%). Compared to RAH patients, those with PA had significantly fewer cardiovascular comorbidities, lower serum potassium levels (4.13 vs. 4.23 mmol/L). Notably, patients with RAH exhibited a faster decline in renal function, specifically an additional 0.7 mL/min/1.73m2 reduction per year (95% CI 0.05 - 1.35, p = 0.03), despite similar baseline eGFR and BP control. In RAH, a continuous association between higher average 24-hour systolic BP and a faster decline in renal function was observed. Systematic screening in aRH reveals a high prevalence of secondary hypertension, particularly PA. Patients with RAH showed significantly worse renal outcomes compared to those with PA, with faster renal decline associated with higher blood pressure within the RAH group, underscoring the need for early diagnosis and strict BP management.